Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Adial Pharmaceuticals, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 295.4K | 240.3K | −55.0K (−18.6%) |
| Value | $298.1K | $152.7K | −$145.4K (−48.8%) |
New holders (2)
Institutions that held Adial Pharmaceuticals, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 26,414 | $17.0K | 0.00% |
| Vanguard Group Inc | 13,159 | $8.34K | 0.00% |
Sold out (3)
Institutions that held Adial Pharmaceuticals, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citadel Advisors LLC | 54,508 | $55.1K |
| Renaissance Technologies LLC | 47,613 | $48.1K |
| Cambridge Investment Research Advisors, Inc. | 27,000 | $27.0K |